Answers are grounded in this paper and cite their sources.
In persons living with HIV, screening for and treating anal cancer precursor lesions, anal high-grade squamous intraepithelial lesions (HSIL), prevents anal cancer. However, screening has not been widely implemented, especially in low- and middle-income countries. We conducted semi-structured qualitative interviews with providers, staff, and patients affiliated with two clinics from the Mexico City HIV program to understand barriers and facilitators to the implementation of a sustainable anal cancer screening program. A limited program for anal cancer screening was already in place at these clinics as part of an international research collaboration. Interviews were conducted in person or by video conference, audio-recorded, transcribed, and thematically analyzed using domains from the Consolidated Framework for Implementation Research. Between October 2023 and June 2024, we conducted 29 interviews, including 17 with physicians or staff and 12 with patients who had undergone anal cancer screening as part of the research collaboration. Participants widely agreed that a permanent program was urgently needed due to high rates of anal HSIL in the population served. Key implementation facilitators included: (1) the alignment of anal cancer screening with existing disease prevention workflows, (2) a strong culture of patient-centered care, and (3) patient motivation for prevention. Key barriers included: (1) patient stigma and limited awareness of screening, (2) challenges related to infrastructure and partnerships, such as lack of trained pathologists and long referral delays, (3) financing concerns in a resource-constrained public health system, and (4) patient-level economic barriers, such as caregiving responsibilities and transportation costs. Physicians and staff proposed adaptations of anal cancer screening to address these challenges, including completing screening in one visit for high-risk patients and tailoring risk-based eligibility criteria to match screening capacity. A small-scale trial program targeting groups at especially high risk of anal cancer was viewed as a promising path to broader implementation. Patients and providers described barriers and facilitators to implementing anal cancer screening, offering insights to guide adaptation and scale-up in Mexico and globally.
No takes yet. Share an insight, caveat, or question.
McClellan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: